A phase I dose escalation study of topical bexarotene in women at high risk for breast cancer
Ended Awarded Last action
- Contract number
- HHSN26100012
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $556,189
Award facts
- Contract value 85% obligated
-
- $556,189.33 Current, with exercised options
- $658,199.33 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$17,060 | |
| Funding Only Action | -$16,868 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Exercise an Option | $106,072 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $102,010 | |
| Original award | $382,036 |
About this award
This is a delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) valued at $658,199.33. The contract is for a phase I dose escalation study of a topical cancer prevention agent, bexarotene, in women at high risk for breast cancer. It is part of the NCI's Cancer Prevention Agent Development Program, an early-phase clinical research initiative. The contract does not have a set-aside designation. MD Anderson is a component of the University of Texas System, a large public university system that receives substantial federal funding for research and education programs across its institutions. Through prime and subcontract awards, MD Anderson has extensive experience conducting cancer-related research, including preclinical studies, epidemiologic investigations, and clinical trials, for various federal agencies.
Quick answers
Who was awarded contract HHSN26100012?
HHSN26100012 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 1, 2017.
How much is contract HHSN26100012 worth?
The government has obligated $556,189 on HHSN26100012. Its potential value, with all options, is $658,199.
Is contract HHSN26100012 an order under another contract?
Yes. HHSN26100012 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100012 competed?
The extent of competition for HHSN26100012 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award